Mutations in PKD1 cause dominant polycystic kidney disease (PKD), characterized by large fluid-filled kidney cysts in adult life, but the molecular mechanism of cystogenesis remains obscure. Ostrom et al (Developmental Biology 219, 250-258, 2000) showed that 
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic diseases in humans, with an incidence of 1:500 to 1:1000 in the general population. Affected individuals normally present in the third or fourth decade of life, although presentation in infancy or in utero has been reported (1, 2) . Typically, ADPKD is characterized by progressive bilateral cyst formation in the kidney, while cysts also commonly form in other organs such as the pancreas, liver, and intestine. Intracranial aneurysm, mitral valve prolapse, and intestinal diverticula are also associated with this disease (reviewed in (3, 4) ). ADPKD accounts for approximately 5% of all patients on renal replacement therapy.
ADPKD is genetically heterogeneous, with 85-90% of ADPKD patients harbouring mutations in the PKD1 gene, encoding polycystin-1, while most of the remaining patients have mutations in PKD2, encoding polycystin-2, and a third locus, PKD3, is thought to exist because PKD segregates independently of PKD1 or PKD2 in a small number of families (3) . In addition to genetic heterogeneity there is phenotypic variability with respect to the severity of the disease, age of onset of end-stage renal failure, and extrarenal manifestations, which vary widely between affected individuals (5) . This notable phenotypic variability is likely to be due to the influence of specific additional genetic loci modifying the rate of onset and/or severity of disease.
Several lines of mice have been reported with targeted mutations in the mouse Pkd1 gene produced by homologous recombination (4) . The first of these Pkd1 "knockout" mice 4 was the del34 Pkd1 knockout mouse, carrying a disruption of exon 34 of the mouse Pkd1 gene, mimicking a mutation in human PKD1, predicted to result in truncation of polycystin-1 (6) . The del34 Pkd1 heterozygous mutant mice progressively developed scattered renal and hepatic cysts in a late onset manner, similar to that seen in human ADPKD. In addition, mislocalization of the epidermal growth factor receptor (EGFR) to the apical membrane of the cystic epithelia, which is a feature of human ADPKD, was demonstrated in the Pkd1 del34/+ heterozygous mutant mice.
Homozygous Pkd1 mutant mice seldom survived to term, exhibiting perinatal lethality and a progressive severe renal cystic phenotype, which commenced at embryonic day 15.5 (E15.5). Histologically, the kidneys developed normally until E14.5, with microscopic dilatation of tubules appearing at E15.5. The number and size of cysts then increased progressively with age, resulting in full-term conceptuses with massively enlarged cystic kidneys, distended abdomens and gross edema.
Each of the murine models of ADPKD strongly support the two-hit hypothesis of ADPKD pathogenesis in that cysts form when kidneys carrying one germline Pkd1 or Pkd2 mutant allele acquire a second somatic mutation in either of these genes (reviewed in (7)). Further support for this theory comes from the identification of mutations in and/or loss of a second allele of PKD1 or PKD2 in isolated human cyst epithelial cells.
Similarly, in a genetically unstable Pkd2 knockout mouse, the second allele of Pkd2 is lost somatically in a stochastic fashion (through recombination). These Pkd2 mutant mice develop a more severe cystic phenotype more rapidly than stable Pkd1 and Pkd2 knockouts, although not as severe as the phenotype of homozygous mutants. Thus in
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Pkd1 homozygous mice the "knockout" of the Pkd1 gene most likely recapitulates in the whole animal events that occur in individual cysts of heterozygous mutants, leading to functional loss of Pkd1.
Mutations in the developmental gene, PAX2, are associated with renal hypoplasia, and renal cysts have occasionally been noted as part of the PAX2-mutant phenotype (8, 9) .
PAX2 is critically required for kidney development, as Pax2 null mutant mice completely lack urogenital tracts, including absent kidneys and ureters (10) . In contrast, overexpression of Pax2 in transgenic mice leads to multicystic kidney disease (11) . Moreover, Pax2 expression has been observed in the cystic epithelia of several types of polycystic kidney disease, suggesting that the expression of Pax2 may be of fundamental importance during cystogenesis (12, 13). Ostrom et al, (14) examined the role of Pax2 in cystogenesis in Cpk mice, which carry a mutation in cystin, an autosomal recessive polycystic kidney disease gene. By crossing Pax2 mutant mice with Cpk mice, a significant inhibition of renal cyst growth in fetal kidneys of the double mutant offspring was observed, which was apparently due to increased apoptosis in the cyst epithelium (14) . Therefore, reduced Pax2 dosage was able to modulate the cystic phenotype in Cpk mice, a recessive model of polycystic kidney disease.
To determine whether Pax2 gene dosage influences the severity of autosomal dominant polycystic kidney disease, we crossed Pkd1 mutant mice with Pax2 mutant mice, and examined the effect on cystogenesis in the offspring. Homozygous Pkd1 del34/del34 mutant mice carrying a heterozygous Pax2 1Neu/+ mutation showed a marked reduction in cyst number and size compared to homozygous Pkd1 mutants carrying a wildtype Pax2 gene. (16) . The mechanism of reduced nephrogenesis in Pax2 1Neu/+ mutants was shown to be due to enhanced apoptosis in the ureteric bud epithelium between E16.5 and E18.5 of kidney development (16) (17) (18) . Accordingly, either Pax2 expression or enhanced cell survival within the arborizing fetal ureteric bud was sufficient to promote increased branching morphogenesis and enhanced nephrogenesis in fetal kidneys (16, 17, (19) (20) (21) .
To investigate the effect of Pax2 haploinsufficiency on cystogenesis in Pkd1 mutant mice were dissected at E15.5, E16.5, E17.5 and E18.5, weighed, and kidneys dissected for morphometric, and immunohistochemical studies.
A clear reduction in the appearance of cysts in Pkd1 del34/del34 /Pax2 1Neu/+ double mutant kidneys was visible in H&E stained sections of E18.5 fetal mice when compared to Pkd1 del34/del34 homozygous mutant kidneys at the same age ( Fig 3A) . The total cyst and lumen volume in Pkd1 del34/del34 /Pax2 1Neu/+ double mutant kidneys was on average less than half that in Pkd1 del34/del34 homozygous mutant kidneys (p=0.021), and similar to that of wild type kidneys when measured using stereological methods ( Fig 3B) .
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At E18.5 Pkd1 del34/del34 kidneys weighed approximately twice as much as wildtype kidneys (Fig 4) . Non-cystic kidneys from mice with a Pax2 1Neu/+ heterozygous mutation were on average 30% lighter than wild type kidneys, and were much smaller than the homozygous mutant Pkd1 del34/del34 kidneys (p<0.001). Pkd1 del34/del34 /Pax2 1Neu/+ double mutant kidneys were much lighter than Pkd1 del34/del34 kidneys (p<0.001), and were instead similar in weight to Pax2 1Neu/+ heterozygous mutant kidneys (Fig 4) . Similar results were obtained when kidney weight to body weight ratios were calculated (data not shown). At E17.5, a similar profile of kidney weights to that at E18.5 was obtained, while at E15.5 the differences in kidney mass between the different genotypes due to cystogenesis were not yet discernable (Supplementary data Fig 1A, B) .
Neither cell proliferation nor apoptosis was altered in cystic kidneys from

Pax2
1Neu/+ /Pkd1 del34/del34 mice when compared to Pkd1 del34/del34 mice
To investigate whether the Pax2 mutation in double mutant Pkd1
/Pax2 1Neu/+ mice caused reduced cyst size by either reducing cell proliferation, or by elevating levels of apoptosis in the cyst epithelium, fetal kidneys of mice at E17.5 carrying the four different genotypes were analyzed using either BrdU incorporation to examine the number of cells undergoing DNA synthesis, or TUNEL staining to examine apoptosis. For the proliferation analysis, fetal mice were exposed in utero to a pulse of BrdU, their kidneys dissected at E17.5, and the kidneys processed using unbiased stereological techniques.
The results from each stage showed that the presence of a Pax2 1Neu/+ heterozygous mutation together with the Pkd1 del34/del34 homozygous mutation did not significantly alter the rate of either cell division or apoptosis in the kidneys compared to the rate in cystic Pkd1 del34/del34 kidneys that lacked the Pax2 mutation (Supplementary data Fig 2A, B) . We then hypothesized that during cystogenesis, Pax2 expression may persist longer in Pkd1 del34/del34 ureteric bud epithelia than normal, and might fail to attenuate in the mature collecting duct epithelia of Pkd1 -/-kidneys, thereby leading to cystogenesis. A detailed examination of Pax2-stained kidney sections from homozygous Pkd1 del34/del34 mutant mice showed that, when compared to wild type mice, Pax2 protein was indeed expressed persistently along the length of the ureteric buds at levels similar to that in normal cells, and unlike wild type or Pkd1 del34/+ kidneys, remained expressed in Pkd1 del34/del34 ureteric buds even as they developed into collecting ducts, some of which could be seen to be in the process of cyst formation (Fig 5B-D) .
Pax2 is persistently expressed in
Pax2 is repressed by human Polycystin-1 in MDCK cells.
We reasoned that Polycystin-1 must repress the expression of Pax2 in nascent nephrons and tubules during normal renal development, and that by lowering the level of Pax2 in cystic kidneys using the Pax2 It was not practical to demonstrate that Pax2 gene dosage had an effect on cystogenesis in Pkd1 del34/+ heterozygous mice, because cystogenesis was too infrequent. However, the influence of reduced Pax2 gene dosage on cystogenesis in heterozygous Pkd1 mutants would be expected to be similar to that observed in Pkd1 del34/del34 homozygotes. Cysts that 14 form in heterozygous Pkd1 mutant mice and humans with ADPKD are thought to contain a somatic mutation in the remaining allele of the Pkd1 gene. Therefore, in heterozygous mice the "second hit" mutation in Pkd1 is thought to be a stochastic somatic event, whereas in homozygous mutant mice the "second hit" is inherited through the germline.
Although cystogenesis was ameliorated in homozygous Pkd1 del34/del34 mice carrying a Pax2 1Neu/+ mutation, these mice did not exhibit greater survival than Pkd1 del34/del34 mice, probably because homozygous Pkd1 del34/del34 mutant mice died as a result of polyhydramnios, hydrops fetalis, spina bifida occulta, osteochondrodysplasia, or other uncharacterized abnormalities that were not influenced by the Pax2 mutation (6).
Cyst formation in recessive Cpk polycystic kidney mouse was ameliorated by Pax2
haploinsufficiency similar to that in Pkd1 del34 mice (14) . However, contrary to our expectations, and in contrast to the observation that increased apoptosis caused by Pax2 haploinsufficiency in the cystic kidneys reported in Ostrom et al (14) , the presence of a Pax2 mutation did not markedly reduce cell proliferation or elevate apoptosis levels in the cysts of Pkd1 homozygous mutant kidneys between E15.5 and E17.5. These data suggest that significantly altered levels of apoptosis or proliferation during this window of time in embryonic development was not the mechanism by which Pax2 haploinsufficiency inhibited cyst formation in Pkd1 mutant mice, although the possibility that Pax2 haploinsufficiency led to more subtle effects on apoptosis or proliferation over a longer period of time, which then impacted on cystogenesis, could not be ruled out.
It would appear, however, that unattenuated expression of Pax2 in ureteric bud and epithelia derived from mesenchymal condensates during kidney development contributed 
MATERIALS AND METHODS
Mouse breeding, tissue isolation, and genotyping
Heterozygous mutant
Immunohistochemistry
Pax2, aquaporin 1 and aquaporin 2 staining was carried out as previously described (16) .
The Pax2 primary antibody was rabbit anti Pax2 (Zymed, San Francisco, CA) (1:50). The aquaporin primary antibodies (rabbit anti-rat) were a gift from Dr Jennifer Bedford. The secondary antibody was a biotinylated goat anti-rabbit (ABC kit, Vector Laboratories, Burlingame, CA), and detection of immunohistochemical labeling was carried out using diaminobenzidine tetrachloride detection (DAB) as the chromagen, with haematoxylin counterstaining.
Stereological analysis of mutant and wild type kidneys
Whole fetal kidneys (Pkd1 ) were fixed, embedded in paraffin, and serial sectioned through the whole kidney at a thickness of 4 μM. Six pairs of sections were selected in a systematic uniform manner starting from a randomly chosen first section. BrdU staining was carried out using a BrdU in-situ detection kit following the manufacturer's recommendations (BD PharMingen, San Diego, USA). BrdU-stained kidney sections were photographed, printed as photomontages, and counting of positively stained nuclei was carried out as previously described (16) . TUNEL labeling was carried out using an in situ cell death detection kit following the manufacturer's recommendations (Roche Diagnostics, Hoffman-La Roche Ltd, Basel, Switzerland). TUNEL-labeled sections were analysed as digital images. A further set of eight sections, also with a randomly chosen first section, were selected systematically and analysed using stereological grids to estimate the volume and also the luminal content of each kidney, using the Cavalieri method as previously described (24) . The volume and lumenal content was determined using the point-sample intercept method. To determine whether the total number of cells in kidneys from different genotypes was variable, an estimate of the tissue volume minus lumen content, as well as the cell density minus lumen content was made. To obtain total tissue volumes (minus the cyst or lumenal volumes) of the kidney for each genotype, the lumenal and/or cyst volumes were subtracted from total volumes of the E17.5 kidneys.
Having done this it was found that the total tissue volumes of the E17. 
Western Immunoblotting
Proteins were isolated from transfected cells using a lysis buffer consisting of 8M urea, 0.1mM EDTA, 4% SDS and 40mM Tris-HCL pH6.8. Thirty micrograms of total protein lysate were diluted in 62.5mM Tris-HCL pH6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.004% bromophenol blue and boiled prior to loading into the gel.
Samples were subjected to SDS-polyacrylamide gel electrophoresis using a 10% separating gel. Samples were transferred to a nitrocellulose membrane, treated with blocking buffer (5% dry milk in PBS-tween 0.1%), probed with rabbit polyclonal anti- 
